Article info

Download PDFPDF

Short report
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers

Authors

  • Katerina Chatzidionysiou Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Karolinska Institutet Department of Medicine Solna, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Bénédicte Delcoigne Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Karolinska Institutet Department of Medicine Solna, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Thomas Frisell Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Karolinska Institutet Department of Medicine Solna, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Merete L Hetland DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, DenmarkDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Bente Glintborg DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, DenmarkDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • lene dreyer Department of Rheumatology, Aalborg University Hospital, Aalborg, DenmarkDepartment of Clinical Medicine, Aalborg Universitet, Aalborg, Denmark PubMed articlesGoogle scholar articles
  • René Cordtz Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte Hospital, The Parker Institute, Frederiksberg Hospital Parker Institute, Frederiksberg, Denmark PubMed articlesGoogle scholar articles
  • Kristian Zobbe Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte Hospital, The Parker Institute, Frederiksberg Hospital Parker Institute, Frederiksberg, Denmark PubMed articlesGoogle scholar articles
  • Dan Nordström Helsinki University and Hospital (ROB-FIN), Departments of Medicine and Rheumatology, Helsinki University Central Hospital, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Nina Trokovic Helsinki University and Hospital (ROB-FIN), Departments of Medicine and Rheumatology, Helsinki University Central Hospital, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Kalle Aaltonen Pharmaceuticals Pricing Board, Ministry of Social Affairs and Health, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Sella Aarrestad Provan Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway PubMed articlesGoogle scholar articles
  • Gerdur Grondal Department of Rheumatology and Centre for Rheumatology Research, National University Hospital of Iceland, Reykjavik, Iceland PubMed articlesGoogle scholar articles
  • Bjorn Gudbjornsson Centre for Rheumatology Research, University Hospital, and Faculty of Medicine, University of Iceland, Reykjavik, Iceland PubMed articlesGoogle scholar articles
  • Johan Askling Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Karolinska Institutet Department of Medicine Solna, Stockholm, Sweden PubMed articlesGoogle scholar articles
  1. Correspondence to Katerina Chatzidionysiou; aikaterini.chatzidionysiou{at}ki.se
View Full Text

Citation

Chatzidionysiou K, Delcoigne B, Frisell T, et al
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers

Publication history

  • Received June 16, 2020
  • Revision received August 18, 2020
  • Accepted August 18, 2020
  • First published September 8, 2020.
Online issue publication 
September 08, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.